- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT04446650
Un estudio de fedratinib en sujetos japoneses con DIPSS (Dynamic International Prognostic Scoring System): mielofibrosis primaria (PMF) de riesgo intermedio o alto, mielofibrosis posterior a la policitemia vera (MF posterior a la PV) o mielofibrosis posterior a la trombocitemia esencial (posterior a la TE) FM)
Un estudio de fase 1/2, multicéntrico, de un solo grupo, abierto para evaluar la eficacia y la seguridad de fedratinib en sujetos japoneses con DIPSS (Dynamic International Prognostic Scoring System), mielofibrosis primaria (PMF) de riesgo intermedio o alto, post- Policitemia Vera Mielofibrosis (Post-PV MF), o Post-Trombocitemia Mielofibrosis esencial (Post-ET MF)
The study will be conducted in compliance with the International Council for Harmonisation (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use/Good Clinical Practice (GCP) and applicable regulatory requirements.
This is a Phase 1/2 multicenter, single arm, open-label study in Japanese subjects with DIPSS intermediate or high-risk PMF, post-PV or post-ET MF. The study consists of 2 parts: Phase 1 part to determine safety and tolerability and a RP2D. The Phase 1 portion of the study will explore one or more drug doses for fedratinib (300 mg and 400 mg) using a mTPI-2 design. Following completion of dose escalation and determination of MTD and/or a RP2D, the study will progress into the Phase 2 part to further evaluate the efficacy and safety.
The study will consist of 3 periods: a Screening Period, a Treatment Period including a 30-day follow-up after last dose visit and a survival follow-up period.
Descripción general del estudio
Tipo de estudio
Inscripción (Actual)
Fase
- Fase 2
- Fase 1
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
-
Aomori, Japón, 030-8553
- Local Institution - 002
-
Bunkyō City, Japón, 113-8677
- Local Institution - 004
-
Fukuoka, Japón, 812-8582
- Local Institution - 015
-
Hitachi, Ibaraki, Japón, 317-0077
- Local Institution - 018
-
Isehara City, Kanagawa, Japón, 259-1193
- Local Institution - 005
-
Kamogawa, Japón, 296-8602
- Local Institution - 010
-
Kitakyushu, Japón, 806-8501
- Local Institution - 017
-
Kumamoto, Japón, 8628655
- Local Institution - 020
-
Maebashi, Japón, 371-8511
- Local Institution - 013
-
Miyazaki, Japón, 889-1692
- Local Institution - 012
-
Nagasaki, Japón, 8528511
- Local Institution - 009
-
Osaka, Japón, 545-8586
- Local Institution - 016
-
Sapporo, Japón, 003-0006
- Local Institution - 014
-
Shinagawa-ku, Tokyo, Japón, 141-8625
- Local Institution - 007
-
Shinjuku, Japón, 162-8666
- Local Institution - 008
-
Shinjyuku-ku, Japón, 160-0023
- Local Institution - 003
-
Takamatsu, Japón, 760-0017
- Local Institution - 019
-
Ōsaka-sayama, Japón, 589-8511
- Local Institution - 011
-
-
Nagano
-
Suwa, Nagano, Japón, 392-8510
- Local Institution - 021
-
-
Tokyo
-
Bunkyo-ku, Tokyo, Japón, 113-8431
- Local Institution - 001
-
-
Yamanashi
-
Chūō, Yamanashi, Japón, 409-3898
- Local Institution - 006
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
Subjects must satisfy the following criteria to be enrolled in the study:
-
Subject is ≥ 20 years of age at the time of signing the informed consent form (ICF)
-
Subject has an Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0, 1 or 2
-
Subject has diagnosis of Primary myelofibrosis (PMF) according to the 2016 World Health Organization (WHO) criteria, or diagnosis of post-ET or post- Polycythemia vera (PV) Myelofibrosis (MF) according to the IWG-MRT 2007 criteria, confirmed by the most recent local pathology report
-
Subject has a Dynamic International Prognostic Scoring System (DIPSS) Risk score of Intermediate-1 with symptom(s), Intermediate-2 or High
-
Subject has a measurable splenomegaly during the screening period as demonstrated by spleen volume of ≥ 450 cm3 by magnetic resonance imaging (MRI) or computed tomography (CT) scan or by palpable spleen measuring ≥ 5 cm below the left costal margin.
-
Subject must meet at least one of the following criteria of (a or b).
Note: reason to discontinue ruxolitinib treatment (lack of efficacy and/or intolerability, etc) and physician decision as to the study participation as being appropriate should be recorded in the case report form:
- Previously received ruxolitinib treatment for PMF or post-PV MF or post-ET MF for at least 14 days (exposure of < 14 days is allowed for subjects who discontinued ruxolitinib due to intolerability or allergy).
- Never received ruxolitinib treatment and is expected to derive clinical benefit from this study participation based on the clinical judgement of the Investigator Only those subjects who previously received ruxolitinib treatment are eligible for the Phase 1 part of the study to avoid overestimating tolerability of fedratinib.
-
Subject must have treatment-related toxicities from prior therapy resolved to Grade 1 or pretreatment baseline before start of last therapy prior to starting the fedratinib treatment.
-
Subject must understand and voluntarily sign an ICF prior to any study-related assessments/procedures being conducted.
-
Subject is willing and able to adhere to the study visit schedule and other protocol requirements.
-
A female of childbearing potential (FCBP) must:
- Have 2 negative pregnancy tests as verified by the Investigator during screening prior to starting fedratinib treatment. She must agree to ongoing pregnancy testing during the course of the study, and after end of fedratinib treatment. This applies even if the subject practices true abstinence* from heterosexual contact.
- Either commit to true abstinence* from heterosexual contact (which must be reviewed on a monthly basis and source documented) or agree to use and be able to comply with highly effective contraception** without interruption, -14 days prior to starting investigational product, during the fedratinib treatment (including dose interruptions), and for 30 days after discontinuation of fedratinib treatment.
- If breastfeeding, agree to stop breastfeeding prior to the participation in the study and not to resume breastfeeding for at least 30 days after treatment discontinuation of the fedratinib treatment.
Note: A female of childbearing potential (FCBP) is a female who: 1) has achieved menarche at some point, 2) has not undergone a hysterectomy or bilateral oophorectomy, or 3) has not been naturally postmenopausal (amenorrhea following cancer therapy or amenorrhea due to other medical reasons does not rule out childbearing potential) for at least 24 consecutive months (ie, has had menses at any time in the preceding 24 consecutive months).
-
A male subject must:
Practice true abstinence (which must be reviewed on a monthly basis) or agree to use a condom during sexual contact with a pregnant female or a female of childbearing potential while participating in the study, during dose interruptions and for at least 30 days following fedratinib discontinuation, or longer if required by local regulations, even if he has undergone a successful vasectomy.
True abstinence is acceptable when this is in line with the preferred and usual lifestyle of the subject. (Periodic abstinence [eg, calendar, ovulation, symptothermal, postovulation methods] and withdrawal are not acceptable methods of contraception).
Agreement to use highly effective methods of contraception that alone or in combination resulting in a failure rate of a Pearl index of less than 1% per year when used consistently and correctly throughout the course of the study. Such methods include combined (estrogen and progestogen containing) hormonal contraception (oral), progestogen-only hormonal contraception associated with inhibition of ovulation (oral), placement of an intrauterine device, placement of an intrauterine hormone-releasing system, bilateral tubal occlusion, and vasectomized partner.
Exclusion Criteria:
The presence of any of the following will exclude a subject from enrollment:
-
Any of the following laboratory abnormalities:
- Platelets < 50 x 109/L (without platelet transfusion)
- Absolute neutrophil count (ANC) < 1.0 x 109/L
- White blood count (WBC) > 100 x 109/L
- Myeloblasts ≥ 5 % in peripheral blood
- Estimated creatinine clearance < 30 mL/min (as estimated by Cockcroft-Gault formula)
- Serum amylase or lipase > 1.5 x upper limit of normal
- Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 3 x upper limit of normal (ULN)
- Total bilirubin > 1.5 x ULN, subject's total bilirubin between 1.5 - 3.0 x ULN are eligible if the direct bilirubin fraction is < 25% of the total bilirubin.
-
Subject is pregnant or breastfeeding female.
-
Subject with previous splenectomy
-
Subject with previous or planned hematopoietic Stem-cell transplantation (SCT)
-
Subject with prior history of Encephalopathy, including Wernicke encephalopathy (WE)
-
Subject with signs or symptoms of encephalopathy, including WE (eg, severe ataxia, ocular paralysis or cerebellar signs) without documented exclusion of WE by thiamine level and brain MRI
-
Subject with thiamine deficiency, defined as thiamine levels in whole blood below normal range according to institutional standard and not demonstrated to be corrected prior to starting the fedratinib treatment
-
Subject with concomitant treatment with or use of pharmaceutical, herbal agents or food known to be strong or moderate inducers of Cytochrome P450 (CYP) 3A4, and dual CYP2C19 and CYP3A4 inhibitors
-
Subject on any chemotherapy, immunomodulatory drug therapy (eg, thalidomide, interferon-alpha), anagrelide, immunosuppressive therapy, systemic corticosteroids > 10 mg/day prednisone or equivalent. Subjects who have had prior exposure to hydroxyurea (eg, Hydrea) in the past may be enrolled into the study as long as it has not been administered within 14 days prior to starting the fedratinib treatment.
-
Subject on treatment with myeloid growth factor (eg, granulocyte-colony stimulating factor [G-CSF]) within 14 days prior to starting the fedratinib treatment
-
Subject with previous exposure to JAK inhibitor(s) other than ruxolitinib treatment
-
Subject has received ruxolitinib within 14 days prior to starting the fedratinib treatment
-
Subject on treatment with aspirin with doses > 150 mg daily
-
Subject with major surgery within 28 days prior to starting the fedratinib treatment
-
Subject with diagnosis of chronic liver disease (eg, chronic alcoholic liver disease, autoimmune hepatitis, sclerosing cholangitis, primary biliary cirrhosis, hemochromatosis, non-alcoholic steatohepatitis)
-
Subject with prior malignancy other than the disease under study unless the subject has not required treatment for the malignancy for at least 3 years prior to the start of fedratinib treatment. However, subject with the following history/concurrent conditions provided successfully treated may enroll: non-invasive skin cancer, in situ cervical cancer, carcinoma in situ of the breast, incidental histologic finding of prostate cancer (T1a or T1b using the tumor, nodes, metastasis [TNM] clinical staging system), or is free of disease and on hormonal treatment only
-
Subject with uncontrolled congestive heart failure (New York Heart Association Classification 3 or 4)
-
Seropositive for and with evidence of active viral infection with hepatitis B virus (HBV)
- Subject who are hepatitis B surface antigen (HBsAg) negative but HB core anti-body (HBcAb) positive or HBsAb positive are eligible in case HBV viral deoxyribonucleoside (DNA) negative
- Subject who had HBsAg positive but show non-detectable viral DNA for at least 6 months prior to starting the fedratinib treatment where appropriate anti-viral treatment should have been given/considered to prevent HBV reactivation based on the standard practice are eligible
- Subject who are seropositive because of hepatitis B virus vaccine are eligible
-
Seropositive for and with active viral infection with hepatitis C virus (HCV)
• Subject who had hepatitis C but show no detectable HCV viral ribonucleotide (RNA) for at least 6 months prior to starting the fedratinib treatment are eligible.
-
Evidence of human immunodeficiency virus (HIV) infection.
-
Subject with serious active infection
• Additionally, subject with history of active severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection within 4 weeks prior to screening, unless the subject has adequately recovered from coronavirus disease (COVID) symptoms and related complications as per investigator's discretion, and following a discussion with the Medical Monitor.
-
Subject with presence of any significant gastric or other disorder that would inhibit absorption of oral medication
-
Subject is unable to swallow capsule
-
Subject with any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from participating in the study
-
Subject has any condition including the presence of laboratory abnormalities, which places the subject at unacceptable risk if the subject were to participate in the study
-
Subject has any condition that confounds the ability to interpret data from the study
-
Subject with participation in any study of an investigational agent (drug, biologic, device) within 30 days prior to starting the fedratinib treatment
-
Subject with a life expectancy of less than 6 months from the planned first dose of fedratinib.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: N / A
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Fedratinib Administration
The fedratinib dose is 300 or 400 mg/day PO (3 or 4 x 100 mg capsules) to be self-administered orally once daily continuously on an outpatient basis, preferably together with food during an evening meal, the same time each day. |
Specified dose on specified days
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Maximum Tolerated Dose (MTD)
Periodo de tiempo: Up to Cycle 1 (each cycle is 28 days)
|
is the highest dose that causes DLTs in not more than 33% of the subjects treated with fedratinib in the first cycle with at least 3 evaluable subjects treated at this dose. |
Up to Cycle 1 (each cycle is 28 days)
|
|
Recommended Phase 2 dose (RP2D)
Periodo de tiempo: Up to Cycle 1 (each cycle is 28 days)
|
is a recommended Phase 2 dose that is determined as safe and tolerable by the Safety Review Committee based on the data from the first cycle with at least 3 evaluable subjects treated at each dose of the Phase 1 part. |
Up to Cycle 1 (each cycle is 28 days)
|
|
Response Rate (RR)
Periodo de tiempo: Up to Cycle 6 (each cycle is 28 days)
|
Proportion of subjects who have ≥ 35% SVR at end of Cycle 6 from baseline |
Up to Cycle 6 (each cycle is 28 days)
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Adverse Events (AEs)
Periodo de tiempo: From ICF signature up until 30 days after last dose of IP
|
An AE is any noxious, unintended, or untoward medical occurrence that may appear or worsen in a subject during the course of a study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the subject's health, including laboratory test values, regardless of etiology. Any worsening (ie, any clinically significant adverse change in the frequency or intensity of a preexisting condition) should be considered an AE. |
From ICF signature up until 30 days after last dose of IP
|
|
Pharmacokinetics - Cmax
Periodo de tiempo: Up to Cycle 1 (each cycle is 28 days)
|
Peak (maximum) plasma concentration of the drug |
Up to Cycle 1 (each cycle is 28 days)
|
|
Pharmacokinetics - AUC
Periodo de tiempo: Up to Cycle 1 (each cycle is 28 days)
|
Area under the plasma concentration curve |
Up to Cycle 1 (each cycle is 28 days)
|
|
Pharmacokinetics - Tmax
Periodo de tiempo: Up to Cycle 1 (each cycle is 28 days)
|
Time to maximum plasma concentration |
Up to Cycle 1 (each cycle is 28 days)
|
|
Symptom response rate (SRR)
Periodo de tiempo: Up to Cycle 6 (each cycle is 28 days)
|
Proportion of subjects with ≥ 50% reduction in total symptom scores measured by MFSAF version 2.0 (Appendix C) at end of Cycle 6 |
Up to Cycle 6 (each cycle is 28 days)
|
|
Spleen volume response rate 25 (RR25)
Periodo de tiempo: Up to Cycle 6 (each cycle is 28 days)
|
Proportion of subjects who have ≥ 25% reduction in spleen volume at the end of Cycle 6 |
Up to Cycle 6 (each cycle is 28 days)
|
|
Spleen Response Rate by Palpation (RRP)
Periodo de tiempo: Up to Cycle 6 (each cycle is 28 days)
|
Proportion of subjects who have ≥ 50% reduction in spleen size by palpation at end of Cycle 6 |
Up to Cycle 6 (each cycle is 28 days)
|
|
Duration of spleen volume response (DR)
Periodo de tiempo: Up to 4 years
|
Duration of ≥ 35% SVR by MRI/CT |
Up to 4 years
|
|
Duration of spleen response by palpation (DRP)
Periodo de tiempo: Up to 4 years
|
Time from the first documented palpable spleen response, according to the IWGMRT 2013 to the time of the first documented loss of response according to the IWG-MRT 2013. |
Up to 4 years
|
|
Duration of symptoms response (DSR)
Periodo de tiempo: Up to 4 years
|
Duration of ≥ 50% reduction in total symptom scores measured by MFSAF version 2.0 |
Up to 4 years
|
|
Spleen and Disease Progression Free Survival (SDPFS)
Periodo de tiempo: Up to 4 years
|
Time from the start of fedratinib treatment to death due to any reason or disease progression (modified IWGMRT 2013 including ≥ 25% increase in spleen volume by MRI/CT) |
Up to 4 years
|
|
Gastrointestinal adverse events
Periodo de tiempo: From ICF signature to the 30-day follow-up after last dose of IP
|
Incidence of subjects with Grade 3 or higher Gastrointestinal events (nausea, diarrhea, or vomiting) according to CTCAE v5.0 |
From ICF signature to the 30-day follow-up after last dose of IP
|
|
Wernicke encephalopathy (WE) events
Periodo de tiempo: From ICF signature to the 30-day follow-up after last dose of IP
|
Occurrence of confirmed Wernicke encephalopathy events |
From ICF signature to the 30-day follow-up after last dose of IP
|
|
Overall Survival (OS)
Periodo de tiempo: Up to 4 years
|
Time from the start of fedratinib treatment to death due to any reason |
Up to 4 years
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Director de estudio: Bristol-Myers Squibb, Bristol-Myers Squibb
- Director de estudio: Bristol Myers Squibb, Bristol-Myers Squibb
Publicaciones y enlaces útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- FEDR-MF-003
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html
Marco de tiempo para compartir IPD
See Plan Description
Criterios de acceso compartido de IPD
See Plan Description
Tipo de información de apoyo para compartir IPD
- PROTOCOLO DE ESTUDIO
- SAVIA
- RSC
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .